IQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance

IQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance




IQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance

  • Revenue of $3,739 million for the fourth quarter, $14,410 million for the full year
  • GAAP Net Income of $227 million for the fourth quarter, $1,091 million for the full year
  • Adjusted EBITDA of $920 million for the fourth quarter, $3,346 million for the full year
  • GAAP Diluted Earnings per Share of $1.20 for the fourth quarter, $5.72 for the full year
  • Adjusted Diluted Earnings per Share of $2.78 for the fourth quarter, $10.16 for the full year
  • R&D Solutions quarterly bookings of over $3.1 billion, representing book-to-bill ratio of 1.51x
  • R&D Solutions contracted backlog of $27.2 billion grew 9.6 percent year-over-year and 11.6 percent excluding the impact of foreign exchange

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2022.

Fourth-Quarter 2022 Operating Results

Revenue for the fourth quarter of $3,739 million increased 2.8 percent on a reported basis and 7.0 percent at constant currency, compared to the fourth quarter of 2021. Technology & Analytics Solutions (TAS) revenue of $1,499 million grew 0.2 percent on a reported basis and 4.7 percent at constant currency. Research & Development Solutions (R&DS) revenue of $2,058 million grew 5.9 percent on a reported basis and 9.3 percent at constant currency. Excluding the impact of pass throughs, R&DS revenue grew 8.6 percent year-over-year on a reported basis. Contract Sales & Medical Solutions (CSMS) revenue of $182 million decreased 7.1 percent on a reported basis and grew 2.0 percent at constant currency.

As of December 31, 2022, R&DS contracted backlog, including reimbursed expenses, was $27.2 billion, growing 9.6 percent year-over-year and 11.6 percent at constant currency. The company expects approximately $7.3 billion of this backlog to convert to revenue in the next twelve months. The fourth-quarter book-to-bill ratio was 1.51x including reimbursed expenses and 1.30x excluding reimbursed expenses. For the year ended December 31, 2022, the book-to-bill ratio was 1.36x including reimbursed expenses and 1.33x excluding reimbursed expenses.

We closed the year with strong results and record bookings and backlog,” said Ari Bousbib, chairman and CEO of IQVIA. “For the full year, we delivered strong underlying revenue growth in all three segments, expanded margins, and again grew Adjusted EPS double digits. The year also marked the end of a very successful Vision 22 plan; we exceeded our three-year goals despite the volatile macro environment over the period. As we begin 2023, the fundamentals of our business and the outlook for our end markets remain healthy. We expect continued robust demand for our differentiated offerings, solid organic growth and sustained operating momentum across the portfolio.”

Fourth-quarter GAAP Net Income was $227 million, down 28.6 percent year-over-year, and GAAP Diluted Earnings per Share was $1.20, decreasing 26.4 percent year-over-year. Adjusted Net Income was $524 million, up 5.6 percent year-over-year, and Adjusted Diluted Earnings per Share was $2.78, up 9.0 percent year-over-year. Adjusted EBITDA was $920 million, increasing 11.1 percent year-over-year.

Full-Year 2022 Operating Results

Revenue of $14,410 million for the full year of 2022 grew 3.9 percent on a reported basis and 7.8 percent at constant currency, compared to 2021. TAS revenue was $5,746 million, up 3.8 percent on a reported basis and 8.7 percent at constant currency. R&DS revenue was $7,921 million, up 4.8 percent on a reported basis and 7.7 percent at constant currency. CSMS revenue was $743 million, down 5.2 percent on a reported basis and up 2.7 percent at constant currency.

For the full year of 2022, GAAP Net Income was $1,091 million, up 12.9 percent year-over-year, and GAAP Diluted Earnings per Share was $5.72, up 15.6 percent year-over-year. Adjusted Net Income was $1,937 million, increasing 10.1 percent year-over-year, and Adjusted Diluted Earnings per Share was $10.16, up 12.5 percent year-over-year. Adjusted EBITDA for the full year of 2022 was $3,346 million, up 10.7 percent year-over-year.

Financial Position

As of December 31, 2022, cash and cash equivalents were $1,216 million and debt was $12,747 million, resulting in net debt of $11,531 million. IQVIA’s Net Leverage Ratio was 3.45x trailing twelve-month Adjusted EBITDA. For the fourth quarter of 2022, Operating Cash Flow was $560 million and Free Cash Flow was $389 million. For the full year of 2022, Operating Cash Flow was $2,260 million and Free Cash Flow was $1,586 million.

During the fourth quarter, the company retired $510 million of a variable rate U.S. dollar term loan, which was scheduled to mature in early 2024.

Share Repurchase

During the fourth quarter of 2022, the company repurchased $25 million of its common stock, resulting in full-year share repurchases of $1,168 million. IQVIA had $1,355 million of share repurchase authorization remaining as of December 31, 2022.

Full-Year 2023 Guidance

For the full year of 2023, the company expects revenue to be between $15,150 million and $15,400 million, representing growth of 5.1 to 6.9 percent on a reported basis and 5.0 to 6.8 percent at constant currency. This revenue guidance assumes about 100 basis points of contribution from acquisitions and approximately $600 million of COVID-related revenue step down versus 2022. The guidance represents 9 to 11 percent revenue growth at constant currency excluding acquisitions and COVID-related work. On the same basis, we expect TAS to grow 7 to 9 percent, R&DS to grow 10 to 12 percent and CSMS approximately 2 percent.

The company expects Adjusted EBITDA to be between $3,625 million and $3,695 million, representing growth of 8.3 to 10.4 percent.

Adjusted Diluted Earnings per Share is expected to be between $10.26 and $10.56, up 1.0 to 3.9 percent. This Adjusted Diluted Earnings per Share guidance includes the year-over-year impact of the step-up in interest rates and the increase in the UK corporate tax rate. Together, these non-operational items impact the year-over-year growth rate by approximately 10 percentage points. Excluding these items, Adjusted Diluted Earnings per Share is expected to grow 11 to 14 percent.

All financial guidance assumes foreign currency exchange rates as of February 8, 2023 remain in effect for the forecast period.

Webcast & Conference Call Details

IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its fourth-quarter and full-year 2022 results and 2023 guidance. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants connect to the call using the information provided in the confirmation email and will be placed directly into the call.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our full-year 2023 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward looking statements contain these identifying words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, international conflicts or other disruptions outside of our control such as the current situation in Ukraine and Russia; our ability to accurately model or forecast the impact of the spread and/or containment of COVID-19, including any variants, among other sources of business interruption, on our operations and financial results; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; government regulators or our customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions, inflation, and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to our business, see the “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”), as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Note on Non-GAAP Financial Measures

This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States (“GAAP”), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted Earnings per Share, and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, the Company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements and trademarks, trade names and other from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income attributable to IQVIA Holdings Inc. As a result, internal management reports feature non-GAAP measures and are used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. Our full-year 2023 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based compensation and other items not reflective of the company’s ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP.

IQVIAFIN

Table 1

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(preliminary and unaudited)

 

 

 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

(in millions, except per share data)

 

2022

 

2021

 

2022

 

2021

Revenues

 

$

3,739

 

 

$

3,636

 

 

$

14,410

 

 

$

13,874

 

Cost of revenues, exclusive of depreciation and amortization

 

 

2,407

 

 

 

2,364

 

 

 

9,382

 

 

 

9,233

 

Selling, general and administrative expenses

 

 

583

 

 

 

542

 

 

 

2,071

 

 

 

1,964

 

Depreciation and amortization

 

 

357

 

 

 

262

 

 

 

1,130

 

 

 

1,264

 

Restructuring costs

 

 

13

 

 

 

5

 

 

 

28

 

 

 

20

 

Income from operations

 

 

379

 

 

 

463

 

 

 

1,799

 

 

 

1,393

 

Interest income

 

 

(6

)

 

 

(2

)

 

 

(13

)

 

 

(6

)

Interest expense

 

 

128

 

 

 

90

 

 

 

416

 

 

 

375

 

Loss on extinguishment of debt

 

 

 

 

 

1

 

 

 

 

 

 

26

 

Other (income) expense, net

 

 

(18

)

 

 

(2

)

 

 

33

 

 

 

(130

)

Income before income taxes and equity in (losses) earnings of unconsolidated affiliates

 

 

275

 

 

 

376

 

 

 

1,363

 

 

 

1,128

 

Income tax expense

 

 

48

 

 

 

59

 

 

 

260

 

 

 

163

 

Income before equity in (losses) earnings of unconsolidated affiliates

 

 

227

 

 

 

317

 

 

 

1,103

 

 

 

965

 

Equity in (losses) earnings of unconsolidated affiliates

 

 

 

 

 

1

 

 

 

(12

)

 

 

6

 

Net income

 

 

227

 

 

 

318

 

 

 

1,091

 

 

 

971

 

Net income attributable to non-controlling interests

 

 

 

 

 

 

 

 

 

 

 

(5

)

Net income attributable to IQVIA Holdings Inc.

 

$

227

 

 

$

318

 

 

$

1,091

 

 

$

966

 

Earnings per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic

 

$

1.22

 

 

$

1.67

 

 

$

5.82

 

 

$

5.05

 

Diluted

 

$

1.20

 

 

$

1.63

 

 

$

5.72

 

 

$

4.95

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

Basic

 

 

185.7

 

 

 

190.8

 

 

 

187.6

 

 

 

191.4

 

Diluted

 

 

188.6

 

 

 

194.8

 

 

 

190.6

 

 

 

195.0

 

Table 2

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(preliminary and unaudited)

 

 

 

December 31,

(in millions, except per share data)

 

2022

 

2021

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

1,216

 

 

$

1,366

 

Trade accounts receivable and unbilled services, net

 

 

2,917

 

 

 

2,551

 

Prepaid expenses

 

 

151

 

 

 

156

 

Income taxes receivable

 

 

43

 

 

 

58

 

Investments in debt, equity and other securities

 

 

93

 

 

 

111

 

Other current assets and receivables

 

 

561

 

 

 

521

 

Total current assets

 

 

4,981

 

 

 

4,763

 

Property and equipment, net

 

 

532

 

 

 

497

 

Operating lease right-of-use assets

 

 

331

 

 

 

406

 

Investments in debt, equity and other securities

 

 

68

 

 

 

76

 

Investments in unconsolidated affiliates

 

 

94

 

 

 

88

 

Goodwill

 

 

13,921

 

 

 

13,301

 

Other identifiable intangibles, net

 

 

4,820

 

 

 

4,943

 

Deferred income taxes

 

 

118

 

 

 

124

 

Deposits and other assets, net

 

 

472

 

 

 

491

 

Total assets

 

$

25,337

 

 

$

24,689

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable and accrued expenses

 

$

3,316

 

 

$

2,981

 

Unearned income

 

 

1,797

 

 

 

1,825

 

Income taxes payable

 

 

161

 

 

 

137

 

Current portion of long-term debt

 

 

152

 

 

 

91

 

Other current liabilities

 

 

152

 

 

 

207

 

Total current liabilities

 

 

5,578

 

 

 

5,241

 

Long-term debt, less current portion

 

 

12,595

 

 

 

12,034

 

Deferred income taxes

 

 

464

 

 

 

410

 

Operating lease liabilities

 

 

264

 

 

 

313

 

Other liabilities

 

 

671

 

 

 

649

 

Total liabilities

 

 

19,572

 

 

 

18,647

 

Stockholders’ equity:

 

 

 

 

Common stock and additional paid-in capital, 400.0 shares authorized as of December 31, 2022 and 2021, $0.01 par value, 256.4 shares issued and 185.7 shares outstanding as of December 31, 2022; 255.8 shares issued and 190.6 shares outstanding as of December 31, 2021

 

 

10,898

 

 

 

10,777

 

Retained earnings

 

 

3,334

 

 

 

2,243

 

Treasury stock, at cost, 70.7 and 65.2 shares as of December 31, 2022 and 2021, respectively

 

 

(7,740

)

 

 

(6,572

)

Accumulated other comprehensive loss

 

 

(727

)

 

 

(406

)

Total stockholders’ equity

 

 

5,765

 

 

 

6,042

 

Total liabilities and stockholders’ equity

 

$

25,337

 

 

$

24,689

 

Table 3

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(preliminary and unaudited)

 

 

 

Year Ended December 31,

(in millions)

 

2022

 

2021

Operating activities:

 

 

 

 

Net income

 

$

1,091

 

 

$

971

 

Adjustments to reconcile net income to cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

 

1,130

 

 

 

1,264

 

Amortization of debt issuance costs and discount

 

 

15

 

 

 

17

 

Stock-based compensation

 

 

194

 

 

 

170

 

Gain on disposals of property and equipment, net

 

 

(10

)

 

 

 

Losses (earnings) from unconsolidated affiliates

 

 

12

 

 

 

(6

)

Loss (gain) on investments, net

 

 

27

 

 

 

(16

)

Benefit from deferred income taxes

 

 

(115

)

 

 

(138

)

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable and unbilled services

 

 

(421

)

 

 

(138

)

Prepaid expenses and other assets

 

 

7

 

 

 

(15

)

Accounts payable and accrued expenses

 

 

427

 

 

 

244

 

Unearned income

 

 

31

 

 

 

591

 

Income taxes payable and other liabilities

 

 

(128

)

 

 

(2

)

Net cash provided by operating activities

 

 

2,260

 

 

 

2,942

 

Investing activities:

 

 

 

 

Acquisition of property, equipment and software

 

 

(674

)

 

 

(640

)

Acquisition of businesses, net of cash acquired

 

 

(1,315

)

 

 

(1,458

)

Purchases of marketable securities, net

 

 

(5

)

 

 

(10

)

Investments in unconsolidated affiliates, net of payments received

 

 

(20

)

 

 

(5

)

Proceeds from sale of (investments in) equity securities

 

 

 

 

 

5

 

Other

 

 

8

 

 

 

5

 

Net cash used in investing activities

 

 

(2,006

)

 

 

(2,103

)

Financing activities:

 

 

 

 

Proceeds from issuance of debt

 

 

1,250

 

 

 

1,951

 

Payment of debt issuance costs

 

 

(5

)

 

 

(40

)

Repayment of debt and principal payments on finance leases

 

 

(634

)

 

 

(2,091

)

Proceeds from revolving credit facility

 

 

2,350

 

 

 

810

 

Repayment of revolving credit facility

 

 

(2,025

)

 

 

(600

)

Payments related to employee stock option plans

 

 

(71

)

 

 

(59

)

Repurchase of common stock

 

 

(1,168

)

 

 

(406

)

Acquisition of Quest’s non-controlling interest

 

 

 

 

 

(758

)

Contingent consideration and deferred purchase price payments

 

 

(26

)

 

 

(42

)

Net cash used in financing activities

 

 

(329

)

 

 

(1,235

)

Effect of foreign currency exchange rate changes on cash

 

 

(75

)

 

 

(52

)

Decrease in cash and cash equivalents

 

 

(150

)

 

 

(448

)

Cash and cash equivalents at beginning of period

 

 

1,366

 

 

 

1,814

 

Cash and cash equivalents at end of period

 

$

1,216

 

 

$

1,366

 

Table 4

IQVIA HOLDINGS INC. AND SUBSIDIARIES

NET INCOME TO ADJUSTED EBITDA RECONCILIATION

(preliminary and unaudited)

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,

 

December 31,

(in millions)

 

2022

 

2021

 

2022

 

2021

Net Income Attributable to IQVIA Holdings Inc.

 

$

227

 

$

318

 

 

$

1,091

 

$

966

 

Provision for income taxes

 

 

48

 

 

59

 

 

 

260

 

 

163

 

Depreciation and amortization

 

 

357

 

 

262

 

 

 

1,130

 

 

1,264

 

Interest expense, net

 

 

122

 

 

88

 

 

 

403

 

 

369

 

(Income) loss in unconsolidated affiliates

 

 

 

 

(1

)

 

 

12

 

 

(6

)

Income from non-controlling interests

 

 

 

 

 

 

 

 

 

5

 

Deferred revenue purchase accounting adjustments

 

 

 

 

3

 

 

 

1

 

 

3

 

Stock-based compensation

 

 

58

 

 

42

 

 

 

194

 

 

170

 

Other expense (income), net (1)

 

 

53

 

 

12

 

 

 

104

 

 

(81

)

Loss on extinguishment of debt

 

 

 

 

1

 

 

 

 

 

26

 

Restructuring and related expenses (2)

 

 

26

 

 

24

 

 

 

73

 

 

68

 

Acquisition related expenses

 

 

29

 

 

20

 

 

 

78

 

 

75

 

Adjusted EBITDA

 

$

920

 

$

828

 

 

$

3,346

 

$

3,022

 

Contacts

Nick Childs, IQVIA Investor Relations (nicholas.childs@iqvia.com)

+1.973.316.3828

Read full story here